Filing Details
- Accession Number:
- 0001104659-22-095856
- Form Type:
- 13D Filing
- Publication Date:
- 2022-08-29 20:00:00
- Filed By:
- Rubric Capital Management
- Company:
- Therapeuticsmd Inc. (NYSEMKT:TXMD)
- Filing Date:
- 2022-08-30
- SEC Url:
- 13D Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Rubric Capital Management | 0 | 1,721,953 | 0 | 1,721,953 | 1,721,953 | 18.27% |
| David Rosen | 0 | 1,721,953 | 0 | 1,721,953 | 1,721,953 | 18.27% |
| SECURITIES AND EXCHANGE COMMISSION |
| Washington, D.C. 20549 |
| SCHEDULE 13D |
| Under the Securities Exchange Act of 1934 |
| (Amendment No. 1)* |
| TherapeuticsMD, Inc. |
| (Name of Issuer) |
| Common Stock, $0.001 par value per share |
| (Title of Class of Securities) |
| 88338N206 |
| (CUSIP Number) |
|
Rubric Capital Management LP 155 East 44th St, Suite 1630 New York, NY 10017 Attention: Brian Kleinhaus 212-418-1888 |
| (Name, Address and Telephone Number of Person |
| Authorized to Receive Notices and Communications) |
| August 23, 2022 |
| (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. ¨
(Page 1 of 5 Pages)
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP No. 88338N206 | SCHEDULE 13D | Page 2 of 5 Pages |
| 1 | NAME OF REPORTING PERSON
Rubric Capital Management LP | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ¨ (b) ¨ | |
| 3 | SEC USE ONLY
| ||
| 4 | SOURCE OF FUNDS
AF | ||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
| ¨ | |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION
State of Delaware | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: | 7 | SOLE VOTING POWER
-0- | |
| 8 | SHARED VOTING POWER
1,721,953 Shares | ||
| 9 | SOLE DISPOSITIVE POWER
-0- | ||
| 10 | SHARED DISPOSITIVE POWER
1,721,953 Shares | ||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
1,721,953 Shares | ||
| 12 | CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
| ¨ | |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
18.27% | ||
| 14 | TYPE OF REPORTING PERSON
PN, IA | ||
| CUSIP No. 88338N206 | SCHEDULE 13D | Page 3 of 5 Pages |
| 1 | NAME OF REPORTING PERSON
David Rosen | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ¨ (b) ¨ | |
| 3 | SEC USE ONLY
| ||
| 4 | SOURCE OF FUNDS
AF | ||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
| ¨ | |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION
United States of America | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: | 7 | SOLE VOTING POWER
-0- | |
| 8 | SHARED VOTING POWER
1,721,953 Shares | ||
| 9 | SOLE DISPOSITIVE POWER
-0- | ||
| 10 | SHARED DISPOSITIVE POWER
1,721,953 Shares | ||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
1,721,953 Shares | ||
| 12 | CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
| ¨ | |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
18.27% | ||
| 14 | TYPE OF REPORTING PERSON
IN | ||
| CUSIP No. 88338N206 | SCHEDULE 13D | Page 4 of 5 Pages |
This Schedule 13D amends the Schedule 13D initially filed by the Reporting Persons with the Securities and Exchange Commission on August 8, 2022, with respect to the common stock, par value $0.001 per share (the “Shares”), of TherapeuticsMD, Inc., a Nevada corporation (the “Issuer”) (collectively, including this amendment, the “Schedule 13D”).
Capitalized terms used but not defined herein have the meanings given to such terms in the Schedule 13D.
| Item 4. | PURPOSE OF TRANSACTION |
Item 4 of the Schedule 13D is hereby amended by adding the following.
As disclosed in an 8-K filed by the Issuer with the United States Securities on August 29, 2022, the Issuer, on and effective as of August 23, 2022, appointed Justin Roberts as an independent director on its board of directors.
| CUSIP No. 88338N206 | SCHEDULE 13D | Page 5 of 5 Pages |
SIGNATURES
After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.
Date: August 30, 2022
| RUBRIC CAPITAL MANAGEMENT LP | |||
| By: | /s/ Michael Nachmani | ||
| Name: Title: | Michael Nachmani Chief Operating Officer | ||
| /s/ David Rosen | |||
| DAVID ROSEN | |||